logo
Share SHARE
FONT-SIZE Plus   Neg

Sanofi Says FDA Oks Auvi-Q For Patients With Life-threatening Allergic Reactions

Sanofi (SNY: Quote) said the FDA has approved Auvi-Q (epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. Auvi-Q is the first-and-only compact epinephrine auto-injector with audio and visual cues that guide patients and caregivers step-by-step through the injection process.

Sanofi US licensed the North American commercialization rights to Auvi-Q from Intelliject, Inc., which has retained commercialization rights for the rest of the world.

"With this FDA approval, Auvi-Q will become the first-and-only epinephrine auto-injector that talks users through each step of the injection process," said Bryan Downey, Vice President, Auvi-Q, Sanofi US. "We are confident that Auvi-Q will provide the up to six million Americans at risk for anaphylaxis and their caregivers an easy-to-use, compact option with unique features to help manage a life-threatening allergic reaction."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
JetBlue Airways is all set to begin direct flights to Cuba from New York beginning July 3. "The Rift delivers on the dream of consumer VR with compelling content, a full ecosystem, and a fully-integrated hardware/software tech stack," the Facebook-owned virtual reality technology firm said. Germanwings co-pilot Andreas Lubitz, who appears to have deliberately crashed the aircraft on French Alps, had rehearsed controlled descent on another flight that morning, investigators said. The crash has killed 150 people aboard the Germanwings Flight 9525 on March 24.
comments powered by Disqus
RELATED NEWS
Trade SNY now with 
Follow RTT